DBV Technologies (NASDAQ:DBVT) Share Price Passes Above 50-Day Moving Average – Should You Sell?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.75 and traded as high as $0.81. DBV Technologies shares last traded at $0.76, with a volume of 60,495 shares.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. HC Wainwright increased their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research report on Tuesday, September 24th. Finally, StockNews.com began coverage on DBV Technologies in a research note on Wednesday. They set a “hold” rating on the stock.

DBV Technologies Price Performance

The stock has a market cap of $73.73 million, a price-to-earnings ratio of -0.83 and a beta of 0.66. The stock’s 50 day simple moving average is $0.75 and its two-hundred day simple moving average is $0.92.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.